they have all the money they need for phase II data, not for approval. Do you know what a phase III trial costs? A lot. Even if they try to get it approved based on phase II, it will take a significant investment of time and money. I promise you they will raise funds again, but hopefully the price will be higher.
The drug makers will be lining up to partner with IMUC when phase 2 data is released. In my opinion, there will probably be a nice premium that will far surpass the costs of the phase 3 trial for ICT-107 and the excess funds can go towards the development of their other pipeline candidates. Current cash position combined with how far along they are with trial puts them in a strong spot to negotiate a lucrative deal.